Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H8N3O4S.Na.H2O |
Molecular Weight | 271.226 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].[O-]S(=O)(=O)CNNC(=O)C1=CC=NC=C1
InChI
InChIKey=VBXBTOGGSZJEEI-UHFFFAOYSA-M
InChI=1S/C7H9N3O4S.Na.H2O/c11-7(6-1-3-8-4-2-6)10-9-5-15(12,13)14;;/h1-4,9H,5H2,(H,10,11)(H,12,13,14);;1H2/q;+1;/p-1
DescriptionCurator's Comment: Description was created based on several sources, including http://www.reference.md/files/C061/mC061382.html
Curator's Comment: Description was created based on several sources, including http://www.reference.md/files/C061/mC061382.html
Methaniazide (metaniazide) is the methanesulfonate derivative of isoniazid with antibacterial properties. It is used used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17962822
Curator's Comment: Administration route: Oral
http://www.druglib.com/reported-side-effects/pyrazinamide/reaction_peritoneal_tuberculosis/
600 mg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000156335
Created by
admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
|
PRIMARY | |||
|
5BH7ED91RW
Created by
admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
|
PRIMARY | |||
|
23724827
Created by
admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
|
PRIMARY | |||
|
SUB130229
Created by
admin on Sat Dec 16 07:49:13 GMT 2023 , Edited by admin on Sat Dec 16 07:49:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD